Navigation Links
Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Date:10/23/2007

th a four day, in-house study period. Post dosing evaluations were conducted for 72 hours in-house, and follow-up visits were scheduled on days seven, 14 and 21.

In this trial, trodusquemine was well tolerated, and there were no serious adverse events reported. In addition to the favorable safety profile of this study, the pharmacokinetic profile of trodusquemine showed a consistent pattern with minimal subject-to-subject variability and linearity across the range of doses studied.

"The safety, tolerability and pharmacokinetics of trodusquemine observed in this study are consistent with the results achieved in preclinical studies," stated Michael Gast, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Genaera. "We look forward to advancing trodusquemine through the clinic in our next set of clinical trials as we study patients with both obesity and type 2 diabetes so that we may potentially provide a monotherapy option for patients afflicted by these disorders."

The Company expects to conduct its second ascending single dose Phase 1 clinical trial (Study MSI-1436C-103) of trodusquemine in obese type 2 diabetics. The trial will evaluate the PK and safety of trodusquemine in this population as well as provide the first opportunity to study short-term glucose control indices, glucose tolerance and insulin sensitivity.

The poster presented at NAASO, "First in Human Use of MSI-1436 (Trodusquemine) a Centrally and Peripherally Acting Selective PTP1B Inhibitor" will be presented today from 9:00 a.m. to 2:30 p.m., Central Time. Clinical researchers from Genaera will be available at the poster from 1:00 p.m. to 2:30 p.m., Central Time to discuss the poster presentation.

About Trodusquemine

Trodusquemine (MSI-1436) is the first drug candidate that acts both centrally and peripherally to selectively inhibit the established and validated enzyme target, protein tyrosine phosphatase 1B (PTP-1B). The dual locations of MSI-1436 a
'/>"/>

SOURCE Genaera Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
2. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
3. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
5. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
6. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
7. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Come fall, many children, teenagers, and ... they want to be for Halloween. And, a number ... decorative contact lenses bought without a prescription. ... people purchase and wear contact lenses without a prescription. ... ® consumer survey, 17 percent of Americans have ...
(Date:9/30/2014)... Sept. 30, 2014 Chindex ... CHDX ) today announced the completion of its acquisition ... per share in cash.  Healthy Harmony is an affiliate ... and Ms. Roberta Lipson , the CEO of ... was adopted by Chindex,s stockholders at a special meeting ...
(Date:9/30/2014)... CARLOS, Calif. , Sept. 30, 2014 /PRNewswire/ ... an additional $10 million investment from current investors ... The additional financing was completed following achievement of ... lead antibody program, and represents an extension of ... closed in December 2012. With this additional financing, ...
Breaking Medicine Technology:The Spooky Truth: What You Need To Know About Contact Lens Hygiene 2The Spooky Truth: What You Need To Know About Contact Lens Hygiene 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 2Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 4Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 5Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 2Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 3Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 4
... BALTIMORE, May 5, 2011 New data presented ... Interventions (SCAI) Scientific Sessions are the first to ... within implantable cardioverter defibrillators (ICDs) to detect restricted ... disease patients outside the hospital setting. Preliminary results ...
... 5, 2011 Echo Therapeutics, Inc. (OTCBB: ECTE), a ... wireless, transdermal continuous glucose monitoring (tCGM) system and the ... the relocation of its corporate headquarters from Franklin, MA ... located in the heart of Philadelphia,s Center City Business ...
Cached Medicine Technology:New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients 2New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients 3Echo Therapeutics Expands Into New Headquarters in Philadelphia 2
(Date:9/30/2014)... 2014 Lea Blackwell, M.D., a Breast ... patients a new, more practical and comfortable option for ... mastectomies, biopsies and lumpectomy surgeries use special bras after ... seeing her patients describe the bra as scratchy, uncomfortable ... new bra in her spare time. , Ilona ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... to reach USD 8,020.1 million by 2020, according ... Inc. Growing demand for personalized medicine and theranostics, ... technologies are expected to be key factors driving ... the growing global base of geriatric population and ...
(Date:9/30/2014)... During this online virtual event, hear ... including achieving hormonal balance, relieving menopause symptoms, breast ... , The details of the virtual ... 2014, Location: Online Event, Registration: Complimentary , Visit ... Monday, October 6th, Steven F. Hotze, M.D., David ...
(Date:9/30/2014)... Oxnard, CA (PRWEB) September 30, 2014 ... the Anacapa Dental Art Institute in Oxnard and Thousand ... Bangalore today and tomorrow to provide training on full ... previous dental work, placing implants, providing cosmetic dentistry, correcting ... Dr. Jivraj said. , Dr. Jivraj, who has traveled ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... ADVISORY** , From:        Hope For ... 910.554.1505, abarnwell(at)hopeforthewarriors(dot)org , ... Celebration , Date:        Thursday, October ... Army and Navy Club, ...
Breaking Medicine News(10 mins):Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 3Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 2Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 3Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 4Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 5Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 6Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2
... D.I.S.C. Spine and,Sports Center, proudly announces ... initial 18 months of operation where over ... Robert S. Bray Jr., founding director and,CEO. ... medical group,providing next generation diagnostics, conservative care, ...
... More than 500 hospital and supplier representatives expected ... all supply chain participants, LOUISVILLE, Colo., March ... will gather in Chicago, April 16-18 for the ... and identify opportunities,for greater collaboration to improve operational ...
... time of year when more,than 1.5 million high school and ... and drink large quantities of alcohol. Students who,vacation with friends ... who stay home with parents or relatives, according to a ... on Alcohol and Drugs., Instead of just telling students ...
... to help caregivers,maintain a sense of balance in their ... the focus of a recently published free Caregiver,s,guide. Today, ... and the free caregivers, guide will help them enhance ... guide provides caregivers with an easy-to-implement and inexpensive,way to ...
... Mich., March 25 Plexus Systems, Inc. ... about efficient manufacturing,operations on Thursday, March 27 ... entitled Smart Manufacturing! Manufacturing IQ & Manufacturing,Operations ... and best practices to achieve quality and ...
... family history are referred less often than whites, study finds ... is a family history of colon cancer, blacks are much ... a new study finds. , While blacks who have an ... their white counterparts in colonoscopy rates, the lack of a ...
Cached Medicine News:Health News:Zero Patient Infections Reported as D.I.S.C. Spine and Sports Center Sets New Standard for Specialty Hospitals 2Health News:The Healthcare Supply Chain to Connect in Chicago for the 2008 GHX Supply Chain Summit 2Health News:It's Spring Break: How Much Does Heavy Drinking Affect Your Body? 2Health News:Free Caregiver's Guide Helps Caregivers & Loved-Ones 2Health News:Plexus Systems, Inc. and Aberdeen Group Co-host March 27 Webinar on Manufacturing Efficiency 2Health News:Plexus Systems, Inc. and Aberdeen Group Co-host March 27 Webinar on Manufacturing Efficiency 3Health News:High-Risk Blacks Less Likely to Get Colonoscopies 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: